false
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Hamburger Menu
CV Risk Beyond LDL!
Cardiovascular (CV) disease is the leading cause of mortality in the US and globally contributing to more than 17 million deaths worldwide. For years, lowering LDL-cholesterol has been one of the primary targets for reducing CV risk, with statins as the established treatment. Recently, new science has emerged and is changing the landscape of how cardiologists and the broader CV team reduce CV risk in their patients. The goal of this page is to provide a resource to highlight the most relevant content on the emerging science in CV risk beyond LDL. Curated content will include new cutting-edge science along with foundational policy, education, and tools.
Guidelines and Policy
Patient Cases
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
2018 ACC/AHA Guideline on the Management of Blood Cholesterol
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Layering Treatment for High-Risk Primary Prevention
Cardiovascular Risk Reduction in a Patient with Diabetes with Risk Factors
The Use of Lipid Modifying Agents in Secondary ASCVD Prevention
Blurred Lines: The High-Risk Patient With Subclinical Atherosclerosis
Hypertriglyceridemia-Induced Pancreatitis During Pregnancy
Journal Scans
Expert Analysis
Omega-3 Fatty Acids for Management of Hypertriglyceridemia - Key Points to Remember
Triglyceride Levels and Increased Medical Care Utilization
Fasting Triglycerides and Prognosis After Acute Coronary Syndrome
Triglycerides and Cardiovascular Disease
Loss-of-Function Mutations in APOC3, Triglycerides and Coronary Disease
Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study
Association Between Plasma Triglycerides and HDL-Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes: A Global Case-Control Study in 13 Countries
Triglyceride-Rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE Study
The Role of Triglycerides in ASCVD Risk (Panel Discussion Part 1)
Triglyceride Lowering Therapies (Panel Discussion Part 2)
Putting It All Together – Guidelines and Beyond (Panel Discussion Part 3)
No One Hit Wonder: High-Dose EPA Reduces Total Ischemic Events
Triglycerides, Remnant Cholesterol and Atherosclerotic Cardiovascular Disease
Hypertriglyceridemia Management According to the 2018 AHA/ACC Guideline
EPA Rises From a Dead Sea of Omega-3: The Landmark REDUCE-IT Trial
Not All Fish Oils Are Created Equal: Insight From REDUCE-IT
New Aspects of the Risk Assessment Guidelines: Practical Highlights, Scientific Evidence and Future Goals
Managing Dyslipidemia in Primary Prevention
Optimizing Non-Fasting Lipid Analysis in the Era of Precision Medicine
How Low Should We Decrease LDL-Cholesterol in a Cost-Effective Manner?
Patients With Very High Triglycerides and Treatment With Omega-3s
Clinical Tools & Patient Resources
Other Articles
ASCVD Risk Estimator Plus
Guideline Clinical App
CardioSmart Very High Triglycerides Condition Center
Images & Slides
Primary Prevention Guideline Slides
REDUCE-IT Total Events Presentation Slides
REDUCE-IT Summary Slide
REDUCE-IT Visual Abstract
REDUCE-IT Presentation Slides
Blood Cholesterol Guideline Slides
FDA Approves Vascepa to Reduce Cardiovascular Risk
A Study of Cardiovascular Events in Diabetes - ASCEND Omega-3
REDUCE-IT: Does Icosapent Ethyl Represent New Pathway For Reducing CV Risk?
Is There Potential Clinical Benefit of Lowering Triglycerides Through LPL Pathway?
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease
Hypertriglyceridemia: Insights on Needs of Cardiologists, CV Team to Reduce Residual Risk
Remnants of Residual Risk: Triglycerides Predict Recurrent Events
Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection.
This collection is supported by Amarin
×
Please select your language
1
English